Clinical Trial Update: Comparative Study of 5 Days of M02-472 Clarithromycin Extended-Release Tablets to 7 Days of Clarithromycin Immediate-Release Tablets for the Treatment of Exacerbation of Chronic Bronchitis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing five days of extended-release clarithromycin (M02-472) to seven days of immediate-release clarithromycin for acute bacterial exacerbatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Exacerbation of Chronic Bronchitis

Drugs mentioned

• Clarithromycin Extended-Release (clarithromycin)
• Clarithromycin Immediate-Release (clarithromycin)

Snippet

Sponsor: Abbott | Conditions: Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB). | Phase 3 | Status: COMPLETED